Cadila Healthcare is expected to show a 55 percent growth year-on-year in its profit at Rs 288.5 crore driven by strong operating income during October-December quarter, according to a CNBC-TV18 poll.
Revenue is seen rising 18 percent to Rs 2,205 crore in the quarter ended December 2014 from Rs 1,872 crore in same quarter last fiscal.
Analysts expect around 35 percent growth in US formulations business of the pharmaceutical company, driven by price hikes in drugs like Hydroxy-Chloroquine and sustained contribution from drugs like Niacin generic. US business growth in Q2FY15 was 68 percent Y-o-Y at Rs 802 crore.
They expect around 20 percent growth in overall export formulations.
Domestic formulation business is expected to show 10-12 percent growth during the quarter, which had been muted in single digits for past six quarters. In Q2FY15, India grew 9 percent mainly due to new pricing policy.
Operating profit may climb 40.7 percent year-on-year to Rs 415.4 crore and margin may expand 304 basis points to 18.84 percent in the quarter gone by. An improvement in operating profit margin may be aided by better business mix and ramp up of new US launches.
Forex volatility in Latin America and commentary on USFDA’s observations of company’s Moraiya facility will be key to watch out for.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
